OSIR - Osiris Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
+0.03 (+0.39%)
At close: 3:14PM EDT
Stock chart is not supported by your current browser
Previous Close7.75
Bid0.00 x 0
Ask0.00 x 0
Day's Range7.78 - 7.78
52 Week Range4.20 - 9.98
Avg. Volume30,482
Market Cap268.612M
PE Ratio (TTM)31.12
EPS (TTM)0.25
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2015-10-14
1y Target Est4.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    Osiris Appoints Willi Miesch to its Board of Directors, Change in CEO

    COLUMBIA, Md., Feb. 06, 2018-- Osiris Therapeutics, Inc. is pleased to announce that its Board of Directors, at a Board Meeting on February 6 th, 2018, appointed Mr. Willi Miesch as a Director, upon recommendation ...

  • ACCESSWIRE5 months ago

    Update in Lawsuit for Investors in Osiris Therapeutics, Inc. (NASDAQ: OSIR) Shares Announced by Shareholders Foundation

    SAN DIEGO, CA / ACCESSWIRE / November 28, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors who purchased NASDAQ: OSIR shares against Osiris Therapeutics, ...

  • Reuters6 months ago

    Former Osiris Therapeutics executive pleads guilty to false statements

    A former chief financial officer of biotechnology company Osiris Therapeutics on Thursday pleaded guilty to making false statements to auditors to inflate the company's reported revenue. Philip Jacoby, 65, entered his plea before U.S. District Judge Denise Cote in in Manhattan, while Osiris separately agreed to pay $1.5 million to settle a related civil lawsuit by the U.S. Securities and Exchange Commission, court records showed. As part of the plea, Jacoby and prosecutors agreed that an appropriate sentence under federal guidelines would be four to 10 months in prison and a fine of up to $5 million.